Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling

被引:13
|
作者
Muratcioglu, Serena [1 ]
Aydin, Cihan [1 ]
Odabasi, Ezgi [2 ,3 ]
Ozdemir, E. Sila [1 ]
Firat-Karalar, Elif Nur [2 ,3 ]
Jang, Hyunbum [4 ]
Tsai, Chung-Jung [4 ]
Nussinov, Ruth [4 ,5 ]
Kavakli, Ibrahim Halil [1 ,2 ,3 ]
Gursoy, Attila [6 ]
Keskin, Ozlem [1 ]
机构
[1] Koc Univ, Res Ctr Translat Med, Dept Chem & Biol Engn, TR-34450 Istanbul, Turkey
[2] Koc Univ, Dept Mol Biol, TR-34450 Istanbul, Turkey
[3] Koc Univ, Dept Genet, TR-34450 Istanbul, Turkey
[4] NCI, Frederick Natl Lab Canc Res, Computat Struct Biol Sect, Frederick, MD 21702 USA
[5] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[6] Koc Univ, Res Ctr Translat Med, Dept Comp Engn, TR-34450 Istanbul, Turkey
基金
美国国家卫生研究院;
关键词
K-Ras4B dimerization; MAPK signaling; interface mutants; membrane localization; K-Ras4B mutation; GROWTH-FACTOR RECEPTORS; RAS FORMS DIMERS; H-RAS; MULTISITE PHOSPHORYLATION; NEGATIVE FEEDBACK; INDUCED APOPTOSIS; PLASMA-MEMBRANE; MEK INHIBITION; WEB SERVER; TRANSCRIPTION;
D O I
10.1016/j.jmb.2020.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ras recruits and activates effectors that transmit receptor-initiated signals. Monomeric Ras can bind Raf; however, Raf's activation requires dimerization, which can be facilitated by Ras dimerization. Previously, we showed that active K-Ras4B dimerizes in silico and in vitro through two major interfaces: (i) beta-interface, mapped to Switch I and effector-binding regions, (ii) alpha-interface at the allosteric lobe. Here, we chose constitutively active K-Ras4B as our control and two double mutants (K101D and R102E; and R41E and K42D) in the alpha- and beta-interfaces. Two of the mutations are from The Cancer Genome Atlas (TCGA) and the Catalogue Of Somatic Mutations In Cancer (COSMIC) data sets. R41 and R102 are found in several adenocarcinomas in Ras isoforms. We performed site-directed mutagenesis, cellular localization experiments, and molecular dynamics (MD) simulations to assess the impact of the mutations on K-Ras4B dimerization and function. alpha-interface K101D/R102E double mutations reduced dimerization but only slightly reduced downstream phosphorylated extracellular signal-regulated kinase (ERK) (pERK) levels. While beta-interface R41E/K42D double mutations did not interfere with dimerization, they almost completely blocked KRas4B-mediated ERK phosphorylation. Both double mutations increased downstream phosphorylated Akt (pAkt) levels in cells. Changes in pERK and pAkt levels altered ERK- and Akt-regulated gene expressions, such as EGR1, JUN, and BCL2L11. These results underscore the role of the alpha-interface in K-Ras4B homodimerization and the beta-surface in effector binding. MD simulations highlight that the membrane and hypervariable region (HVR) interact with both alpha- and beta-interfaces of K-Ras4B mutants, respectively, inhibiting homodimerization and probably effector binding. Mutations at both interfaces interfered with mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase signaling but in different forms and extents. We conclude that dimerization is not necessary but enhances downstream MAPK signaling. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1199 / 1215
页数:17
相关论文
共 50 条
  • [21] DISRUPTION OF ONCOGENIC K-RAS4B PROCESSING AND SIGNALING BY A POTENT GERANYLGERANYLTRANSFERASE-I INHIBITOR
    LERNER, EC
    QIAN, YM
    HAMILTON, AD
    SEBTI, SM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) : 26770 - 26773
  • [22] Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling
    Reynolds, Samuel B.
    Pettit, Kristen
    Kandarpa, Malathi
    Talpaz, Moshe
    Li, Qing
    [J]. CANCERS, 2023, 15 (18)
  • [23] The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction
    Klomp, Jennifer E.
    Klomp, Jeff A.
    Der, Channing J.
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2021, 49 (01) : 253 - 267
  • [24] The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer
    Finegan, Katherine G.
    Tournier, Cathy
    [J]. CANCER RESEARCH, 2010, 70 (14) : 5797 - 5806
  • [25] MAMMALIAN MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE (MEKK) CAN FUNCTION IN A YEAST MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY DOWNSTREAM OF PROTEIN-KINASE-C
    BLUMER, KJ
    JOHNSON, GL
    LANGECARTER, CA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4925 - 4929
  • [26] Nucleotide-Dependent Membrane Interaction and Dimerization of K-Ras4B
    Jang, Hyunbum
    Lu, Shaoyong
    Chakrabarti, Mayukh
    Khavrutskii, Lyuba
    Tarasova, Nadya I.
    Gaponenko, Vadim
    Nussinov, Ruth
    [J]. BIOPHYSICAL JOURNAL, 2015, 108 (02) : 93A - 94A
  • [27] The Kinase Activity-deficient Isoform of the Protein Araf Antagonizes Ras/Mitogen-activated Protein Kinase (Ras/MAPK) Signaling in the Zebrafish Embryo
    Xiong, Cong
    Liu, Xingfeng
    Meng, Anming
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (42) : 25512 - 25521
  • [28] Role of mitogen-activated protein kinase kinase 4 in cancer
    A J Whitmarsh
    R J Davis
    [J]. Oncogene, 2007, 26 : 3172 - 3184
  • [29] Mitogen-Activated Protein Kinase Kinase 4 (MKK4)
    Cuenda, A
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2000, 32 (06): : 581 - 587
  • [30] Role of mitogen-activated protein kinase kinase 4 in cancer
    Whitmarsh, A. J.
    Davis, R. J.
    [J]. ONCOGENE, 2007, 26 (22) : 3172 - 3184